A Genetic and Biochemical Perspective: Acute Coronary Syndrome and Raftlin.

Area of Science:

• Cardiovascular Medicine
• Biomarker Discovery
• Inflammatory Signaling

Background:

• Inflammation is central to acute coronary syndrome (ACS) pathophysiology.
• Raftlin, an inflammatory protein, is a potential cardiovascular disease biomarker.
• This study investigates raftlin levels and RFTN1 rs690037 polymorphism in ACS patients.

Purpose of the Study:

• To evaluate circulating raftlin levels in ACS patients.
• To assess the association between RFTN1 rs690037 polymorphism and ACS.
• To determine raftlin's diagnostic and prognostic utility in ACS.

Main Methods:

• Prospective observational study with 50 ACS patients and 50 controls.
• Serum raftlin measured by ELISA; RFTN1 rs690037 analyzed by real-time PCR.
• Statistical analyses included correlation, ROC, logistic regression, and NRI.

Main Results:

• Serum raftlin levels were significantly higher in ACS patients (p=0.003).
• Raftlin correlated positively with LDL cholesterol and HbA1c in ACS patients.
• Raftlin showed moderate ACS discriminative ability (AUC: 0.672) and improved risk classification (NRI: 0.213, p=0.041).
• No association found between RFTN1 rs690037 polymorphism and ACS or raftlin levels.

Conclusions:

• Elevated circulating raftlin levels in ACS reflect inflammatory and metabolic dysregulation.
• Raftlin has potential as a complementary biomarker for ACS risk assessment.
• Further multicenter studies are needed to confirm raftlin's prognostic and translational significance.